Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Hopkins NK et al. | Acetyl glyceryl ether phosphorylcholine (PAF-acether) and leukotriene B4-mediated neutrophil chemotaxis through an intact endothelial cell monolayer. | 1984 | Biochim. Biophys. Acta | pmid:6089913 |
Emilsson A and Sundler R | Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and ionophore A23187. | 1984 | J. Biol. Chem. | pmid:6321496 |
Hillmar I et al. | Effects of a thio analog of platelet-activating factor on platelet aggregation and adenosine 3',5'-monophosphate concentration in hepatocyte suspensions and in platelets. A comparison with the naturally occurring compound. | 1984 | Hoppe-Seyler's Z. Physiol. Chem. | pmid:6325321 |
Krishnamurthi S et al. | Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. | 1984 | Biochem. Pharmacol. | pmid:6091666 |
Kamitani T et al. | Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. | 1984 | Eur. J. Pharmacol. | pmid:6144557 |
Tokumura A et al. | Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. | 1984 | J. Pharm. Pharmacol. | pmid:6144763 |
Pirotzky E et al. | Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. | 1984 | Kidney Int. | pmid:6144811 |
Gómez-Cambronero J et al. | The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). | 1984 | Biochem. J. | pmid:6146309 |
Rao AK et al. | Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. | 1984 | Am. J. Hematol. | pmid:6431801 |
Colditz IG and Movat HZ | Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. | 1984 | J. Immunol. | pmid:6088633 |
Siess W et al. | Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change. | 1984 | J. Biol. Chem. | pmid:6429141 |
Knauer KA et al. | Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. | 1984 | Int. Arch. Allergy Appl. Immunol. | pmid:6200443 |
Kazimierczak W et al. | Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. | 1984 | Am. Rev. Respir. Dis. | pmid:6201094 |
Malpass TW et al. | The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. | 1984 | J. Thorac. Cardiovasc. Surg. | pmid:6231433 |
Willoughby WF and Willoughby JB | Immunologic mechanisms of parenchymal lung injury. | 1984 | Environ. Health Perspect. | pmid:6234162 |
Wissner A et al. | Analogues of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain. | 1984 | J. Med. Chem. | pmid:6471071 |
Mallet AI et al. | Rapid isocratic high-performance liquid chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. | 1984 | J. Chromatogr. | pmid:6480761 |
Kenzora JL et al. | Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs. | 1984 | J. Clin. Invest. | pmid:6480824 |
Jackson EM et al. | High performance liquid chromatography of platelet-activating factors. | 1984 | J. Lipid Res. | pmid:6481248 |
Dewar A et al. | Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig. | 1984 | J. Pathol. | pmid:6481526 |
Goldstein BM et al. | Effect of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. | 1984 | Life Sci. | pmid:6482659 |
Baldo BA and Tovey ER | Allergy, allergens and allergen standardization. | 1984 | Med. J. Aust. | pmid:6482786 |
Saeki S et al. | Effect of 1-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine on blood pressure by intra-lateral ventricular injection in the rat. | 1984 | Med J Osaka Univ | pmid:6482814 |
Chilton FH et al. | 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. | 1984 | J. Biol. Chem. | pmid:6434535 |
Caramelo C et al. | Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6732788 |
Lenihan DJ and Lee TC | Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6732789 |
Kasuya Y et al. | Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. | 1984 | Can. J. Physiol. Pharmacol. | pmid:6733593 |
Page CP et al. | Platelets and bronchospasm. | 1984 | Int. Arch. Allergy Appl. Immunol. | pmid:6735490 |
Jouvin-Marche E et al. | Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. | 1984 | J. Immunol. | pmid:6736649 |
Ostermann G et al. | Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. | 1984 | Thromb. Res. | pmid:6710440 |
Levi R et al. | Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. | 1984 | Circ. Res. | pmid:6692502 |
Humphrey DM et al. | Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. | 1984 | Lab. Invest. | pmid:6694349 |
Masugi F et al. | Effect of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the rat. | 1984 | Life Sci. | pmid:6694519 |
Bottecchia D et al. | Influence of the pure synthetic PAF (platelet aggregating factor) on clot retraction and platelet aggregation. | 1984 | Scand J Haematol | pmid:6695148 |
Blank ML et al. | A new class of antihypertensive neutral lipid: 1-alkyl-2-acetyl-sn-glycerols, a precursor of platelet activating factor. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6696762 |
Kester M et al. | The potentiation of arterial contraction with platelet activating factor. | 1984 | Pflugers Arch. | pmid:6718228 |
Pelczar-Wissner CJ et al. | Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. | 1984 | Am. J. Hematol. | pmid:6720685 |
Guay DR and Richard A | Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. | 1984 | Drug Intell Clin Pharm | pmid:6723517 |
Poitevin B et al. | Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. | 1984 | Immunopharmacology | pmid:6724877 |
Kasuya Y et al. | Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). | 1984 | J. Pharmacobio-dyn. | pmid:6726619 |
McGivern DV and Basran GS | Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in man. | 1984 | Eur. J. Pharmacol. | pmid:6592097 |
Beaubien BB et al. | Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6594998 |
Roubin R et al. | The role of immunomodulators in the production of lipid mediators by macrophages (M phi). | 1984 | Int J Tissue React | pmid:6596298 |
Schleimer RP et al. | Inflammatory mediators and mechanisms of release from purified human basophils and mast cells. | 1984 | J. Allergy Clin. Immunol. | pmid:6208229 |
Nishihira J et al. | Mass spectrometric evidence for the presence of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid during labor. | 1984 | Lipids | pmid:6527609 |
Lefer AM et al. | Pathophysiological mechanisms of sudden death induced by platelet activating factor. | 1984 | Br. J. Pharmacol. | pmid:6435705 |
Gunby P | A new piece for the puzzle of inflammation. | 1984 | JAMA | pmid:6420583 |
Lian EC et al. | Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. | 1984 | Thromb. Res. | pmid:6420930 |
Billah MM and Siegel MI | Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6422930 |
Prevost MC et al. | Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6422938 |